BCG-unresponsive non-muscle invasive bladder cancer

DBCOND0153568NeoplasmsUrogenital Diseases

BCG-unresponsive non-muscle invasive bladder cancer is the indication for 2 drugs in DrugBank. It is covered by 4 curated, structured indications.

Also known as
Non-Muscle Invasive Bladder Cancer ("NMIBC") Unresponsive/Intolerant to BCG
Classified under
Indicated drugs

Resolves to

Vocabularies
ICD-10C67SNOMED CT188248005MedDRA10005013UMLSC0005684

What you can answer from here — as of October 25, 2026

2Indicated drugsWith each drug's targets and mechanism
Listed above
4Structured indicationsPopulation, line of therapy, route and combination as fields, not prose
Sign in
1Clinical trialPhase, status and sponsor resolved per trial
Sign in
1Drug reporting it as an adverse effectWith incidence where the label states it
Sign in

Which approved drugs for BCG-unresponsive non-muscle invasive bladder cancer share a target, and which companies have late-stage candidates against it?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In